

Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: A potential link between genome surveillance and apoptosis

Robert A. Screaton*, Stephan Kiessling*, Owen J. Sansom†, Catherine B. Millar‡, Kathryn Maddison†, Adrian Bird‡, Alan R. Clarke†, and Steven M. Frisch*[§]

*The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037; †Cardiff School of Biosciences, Cardiff University, P.O. Box 911, Cardiff CF10 3US, United Kingdom; and ‡Wellcome Trust Centre for Cell Biology, The King's Buildings, Edinburgh University, Edinburgh EH9 3JR, United Kingdom

Communicated by Erkki Ruoslahti, The Burnham Institute, La Jolla, CA, February 28, 2003 (received for review January 22, 2003)

Fas-associated death domain protein (FADD) is an adaptor protein bridging death receptors with initiator caspases. Thus, its function and localization are assumed to be cytoplasmic, although the localization of endogenous FADD has not been reported. Surprisingly, the data presented here demonstrate that FADD is mainly nuclear in several adherent cell lines. Its accumulation in the nucleus and export to the cytoplasm required the phosphorylation site Ser-194, which was also required for its interaction with the nucleocytoplasmic shuttling protein exportin-5. Within the nucleus, FADD interacted with the methyl-CpG binding domain protein 4 (MBD4), which excises thymine from GT mismatches in methylated regions of chromatin. The MBD4-interacting mismatch repair factor MLH1 was also found in a complex with FADD. The FADD-MBD4 interaction involved the death effector domain of FADD and a region of MBD4 adjacent to the glycosylase domain. The FADD-binding region of MBD4 was downstream of a frameshift mutation that occurs in a significant fraction of human colorectal carcinomas. Consistent with the idea that MBD4 can signal to an apoptotic effector, MBD4 regulated DNA damage-, Fas ligand-, and cell detachment-induced apoptosis. The nuclear localization of FADD and its interaction with a genome surveillance/DNA repair protein that can regulate apoptosis suggests a novel function of FADD distinct from direct participation in death receptor signaling complexes.

DNA damage-induced apoptosis signals originate in the nucleus. For example, double-strand DNA breaks activate the ATM/ATR (1) and c-abl-related kinases (2), leading to activation of the p53-family proteins (3, 4) and subsequent apoptosis. Other forms of DNA damage that are repaired by the mismatch repair (MMR) complex (reviewed in refs. 5 and 6) can promote apoptosis through the MMR component MLH1. Thus, MLH1 defects in tumor cells cause apoptosis resistance with regard to several DNA-damaging drugs (7–11). In fact, all five major types of DNA repair complexes are thought to signal to the apoptotic machinery (reviewed in ref. 12), although the mechanism of signaling is largely unknown.

Interestingly, several apoptosis-regulatory proteins are in the nucleus constitutively or conditionally. These include PEA-15 (13), DEDD 1–3 (14–16), DEDAF (17), p84N5 (18), caspases-2 (19) and -6 (20), Daxx (21), and (under conditions where nuclear export is inhibited) TRADD (22). Possible roles for these proteins in nuclear apoptotic signaling remain to be determined.

Recently, we have identified an additional link between a DNA repair protein and apoptosis (O.J.S. and A.R.C., unpublished data), namely the protein methyl-CpG binding domain protein 4 [MBD4 (23), also known as MED1 (24)]: MBD4 promoted the apoptotic response to DNA-damaging agents. The N-terminal conserved MBD of this protein targets it to bind methylated regions of DNA, whereas the C terminus is a uracil/thymine-*N*-glycosylase. The latter excises spontaneously deaminated cytosine (i.e., uracil) or methylcytosine (i.e., thymine) from G-T/U mismatches (25–27), the major individual

source of point mutations in the human genome (28). MBD4 interacts with the mismatch repair/tumor suppressor protein MLH1 (24); both are mutator genes (29, 30). The inactivation of either gene causes increased apoptosis resistance with regard to DNA-damaging agents (refs. 7–11; O.J.S. and A.R.C., unpublished data), implying possible apoptotic signaling functions for both proteins. As with MLH1 (reviewed in ref. 30), MBD4 and also frequently mutated in certain human tumors (6, 31–34). The mechanistic link between MBD4, MLH1, and apoptosis will be important to elucidate.

Fas-associated death domain protein (FADD) is known mainly for its death receptor adaptor function at the cell surface (35–37). Thus, it is widely assumed that FADD is primarily or solely a cytoplasmic protein. However, there are no published data clearly supporting this assumption (see *Discussion*). Indeed, FADD has been implicated in potentially death receptor-independent apoptotic responses such as DNA damage and anoikis (38–42) that would not necessarily require FADD to be cytoplasmic. Moreover, cell-matrix adhesion can protect against Fas ligand (FasL)-induced apoptosis (R.A.S. and S.M.F., unpublished observations; refs. 43 and 44), suggesting that certain Fas-interacting proteins might be subject to relocalization by extracellular signals. We therefore examined the subcellular localization of FADD in the hope of revealing additional functions of the protein. Here, we report that FADD primarily localized to the nucleus, implying that the nuclear-cytoplasmic transport of FADD must be actively regulated and that FADD may have a novel nuclear function. We report that exportin-5 is a candidate nucleocytoplasmic transport protein for FADD and that a genome surveillance protein, MBD4, interacts directly with FADD and modulates apoptosis, suggesting a novel link between genome surveillance and apoptosis.

Materials and Methods

Cell Lines, Cell Culture, and Transfections. The normal human mammary epithelial cell line MCF10a was used for most experiments in this article. *MBD4*^{-/-} mouse embryo fibroblasts (MEFs) have been described (29). Cells were transfected by using lipofection or infected with retroviruses based on MSCV-ires-zeo (45), and expression of transgenes was checked by Western blotting.

Apoptosis Assays (Cell Culture Experiments). Cells were maintained in low-attachment wells for the indicated times (for anoikis); some cell samples were exposed to recombinant FasL in the presence of enhancer antibody (for FasL). Cell lysates were

Abbreviations: MBD4, methyl-CpG binding domain protein 4; FADD, Fas-associated death domain protein; FasL, Fas ligand; YFP, yellow fluorescent protein; HA, hemagglutinin; NLS, nuclear localization signal; MEF, mouse embryo fibroblast; DED, death effector domain.

[§]To whom correspondence should be addressed. E-mail: sfrisch@burnham.org.

prepared and assayed fluorimetrically for Ac-DEVD-AFC cleavage activity.

Apoptosis Assays (in Vivo Experiments). *MBD4*^{+/+} or *MBD4*^{-/-} mice were injected with the Fas-agonistic antibody Jo-2. Histological sections of the indicated tissues were stained with hematoxylin/eosin and analyzed for apoptosis as described (46).

Antibodies. Most antibodies were obtained from commercial sources; additional FADD polyclonal antibodies were prepared against bacterially produced GST-FADD protein, and a sheep anti-MBD4 was prepared against the C-terminal 180 aa of recombinant MBD4 protein. A detailed characterization of antibodies is presented in Fig. 5, which is published as supporting information on the PNAS web site, www.pnas.org.

Nuclear-Cytoplasmic Fractionation. Nuclear-cytoplasmic fractionation was accomplished by homogenization of cells in hypotonic buffer followed by low-speed (800 × g) centrifugation.

Indirect Immunofluorescence. Indirect immunofluorescence was performed on formaldehyde-fixed, Triton X-100-permeabilized cells by using fluorescently tagged secondary antibodies.

Short-Interfering RNA. Short-interfering RNA was introduced by using lipofection of commercially synthesized RNA duplexes.

FADD Export Assay. WT or mutant forms of FADD were expressed with N-terminal yellow fluorescent protein (YFP) tags and C-terminal nuclear localization signals (NLSs) derived from simian virus 40 virus. After transfection, cells were detached for 15 min before formaldehyde fixation and cells were scored for nuclear vs. cytoplasmic localization on a fluorescence microscope.

Cell Surface Fas Coimmunoprecipitation/Western Blotting. Cell surface Fas coimmunoprecipitation/Western blotting was performed by incubating cell cultures with the Fas-agonistic antibody 2R2 (Roche Molecular Biochemicals) followed by cell lysis in Triton X-100-containing buffer, precipitation with protein A-Sepharose, and Western blot analysis.

Yeast Two-Hybrid Screening, Protein Interactions in Vitro, Western Blotting, and Immunoprecipitation. Yeast two-hybrid screening, protein interactions *in vitro*, Western blotting, and immunoprecipitation were performed by using standard methodology as described in *Supporting Methods*, which is published as supporting information on the PNAS web site.

See *Supporting Methods* for detailed materials and methods.

Results

FADD Localizes to the Nucleus in Several Cell Lines. In the course of examining the basis for protection against FasL-induced apoptosis by cell adhesion (R.A.S. and S.M.F., unpublished work), we observed that FADD was predominantly nuclear by using a mAb (Fig. 1). Nuclear FADD staining was blocked by preincubation of the antibody with recombinant antigen. We then generated two monospecific anti-human FADD polyclonal antibodies, which confirmed that FADD was primarily nuclear (Fig. 1). FADD was also primarily nuclear in several cell lines (HT1080 fibrosarcoma, Caco-2 colorectal carcinoma, HaCat keratinocytes, human umbilical vein endothelial cells) representative of diverse attached cell types (data not shown); lymphocytes were not examined in this study. This staining pattern was not seen with antibodies against another death receptor adaptor protein TRADD (data not shown) in the absence of leptomycin, in agreement with a previous report (22). It was unlikely that fixation and permeabilization selectively leached a non-nuclear




Fig. 1. FADD localizes primarily to the nucleus. (Top) MCF10a cells were analyzed for FADD localization by immunofluorescence using a mAb and a polyclonal antibody (pAb); a second pAb produced similar results (data not shown). Nuclear location is indicated by 4',6-diamidino-2-phenylindole (DAPI) staining. (Middle) Immunofluorescent staining was carried out after incubation of the primary antibody (mAb) with recombinant maltose-binding protein fusion proteins of FADD or c-jun. (Bottom) MCF10a cells were infected with a retrovirus containing HA-tagged FADD and stained with anti-HA antibody. (Inset) Fixation/permeabilization did not extract a detectable pool of FADD. After fixation (lane 2) or fixation plus permeabilization (lane 3) the insoluble fraction was dissolved in SDS sample buffer and analyzed for FADD by Western blotting. Lane 1 contains the soluble fraction from fixation plus permeabilization.

FADD population, because no FADD was found by immunoblotting of the extracted material obtained during these procedures (Fig. 1). Treatment of MCF10a cells with FADD short-interfering RNA reduced both the FADD signal on a Western blot and the average signal intensity of nuclear immunofluorescence (Fig. 6a, which is published as supporting information on the PNAS web site). To confirm the specificity of the nuclear signal, we also generated a monospecific anti-mouse FADD antibody and compared the immunofluorescence micrographs by using FADD-knockout MEFs versus FADD-expressing cells (47). The nuclear FADD signal obtained with an anti-mouse FADD polyclonal antibody was reduced to background levels in FADD-knockout MEFs (Fig. 6a). Also, certain mutants of FADD (described below) were found in the cytoplasm under the same fixation conditions, further excluding the possibility of a “fixation artifact.”

We then tested whether FADD was nuclear by a cell fractionation approach. Hypotonic lysates were subjected to low-speed (800 g) centrifugation, yielding a pellet that was highly enriched for nuclei. Equal cell equivalents of nuclear and cytoplasmic fractions were assayed for FADD content by Western blotting (Fig. 6b), indicating that the majority of FADD protein was in the nuclear fraction, as was the majority of c-jun protein. By contrast, the cytoplasmic protein procaspase-3 was mainly in the cytoplasmic fraction. It is not yet clear whether the small percentage of FADD found in the cytoplasmic fraction in some experiments was caused by leakage from the nucleus during the extraction procedure, the extent of which varies widely among nuclear proteins (48, 49), or represented a minor cytoplasmic pool that escaped immunofluorescent detection.

Taken together, the data strongly indicated that the primary localization of FADD is in the cell nucleus of adherent cell lines.

Exportin-5 Is a Potential FADD-Shuttling Protein. FADD functions at the membrane as a death receptor adaptor protein, implying that either a minor cytoplasmic pool is maintained constitutively or




Fig. 2. Characterization of FADD nuclear import/export. (a) Mutation of the Ser-194 phosphorylation site or of the DED (amino acids 1–80) of FADD increases its cytoplasmic accumulation. HA-FADD expression constructs containing the indicated FADD mutants were transfected into MCF10a cells, which were then immunostained with anti-HA antibody after being maintained in attached conditions. Representative HA-stained cells and the positions of their nuclei (4',6-diamidino-2-phenylindole, DAPI) are shown. (b) The same mutations of FADD that cause cytoplasmic accumulation also prevent induction of export after nuclear localization has been experimentally enforced. YFP-FADD-NLS expression constructs containing WT FADD or mutant FADD sequences linked to three simian virus 40 NLSs were transfected into MCF10a cells. Attached or (15 min) detached cells treated in the presence or absence of a Fas-agonistic antibody (2R2) were then scored for nuclear (N) or nuclear plus cytoplasmic (N + C) localization of the fluorescent tag; representative images used to score the cells are shown (Top), and quantitation of the results is shown in the histogram (Middle). The percentages of NC cells under attached conditions (without 2R2) were on average 2% greater for YFP-FADD-NLS than for YFP-NLS. [A, YFP-NLS; B, YFP-FADD (WT)-NLS; C, YFP-FADD (S194A)-NLS; D, YFP-FADD (Δ 1–80)-NLS.] (Bottom) Detachment of cells from matrix promotes the recruitment of endogenous FADD protein to cell surface Fas-FasL complexes. Cells were incubated with a Fas agonistic mAb (2R2) under attached (A) or suspended (S) conditions for the indicated times; complexes were immunoprecipitated and analyzed for FADD by Western blotting.

that conditions that sensitize the cell to FasL trigger a rapid export of some fraction of FADD from the nucleus. In either event, we suspected that FADD's nucleocytoplasmic transport was likely to be performed actively by a transport protein rather than occurring by diffusion. To investigate the transport mechanism, we noted that FADD is phosphorylated at Ser-194 (50, 51). The function of this phosphorylation is unknown; it is not, however, required for the interaction of FADD with caspase-8 or Fas (50).

When hemagglutinin (HA) epitope-tagged FADD was transfected transiently into MCF10a cells, most cells showed mainly nuclear staining. However, the mutation of Ser-194 to alanine caused the FADD to be almost uniformly distributed throughout the cell (Fig. 2a). Among other mutants tested, the only other alterations similarly affecting FADD localization were either the deletion of the death effector domain (DED) (amino acids 1–80) or point mutation of Phe-25 to a glycine, which disrupts DED homotypic interactions (52). Despite this finding, there was no obvious basic amino acid-containing NLS present in the region of Ser-194 or in the DED, suggesting an unusual import mechanism (discussed below).

We then established an assay for the nuclear export of FADD in which YFP-labeled FADD was forced to assume a nuclear localization at time 0, regardless of FADD mutations, caused by three simian virus 40 NLSs appended to the C terminus. This

assay allowed us to assay mutants that were potentially defective in both import and export for export specifically. We found that a brief period of cell detachment from matrix caused the WT YFP-FADD-NLS to partially export from the nucleus, producing a nuclear-plus-cytoplasmic signal in \approx 20–25% of the cells in 15 min, whereas the control YFP-NLS remained in 95% of the nuclei (Fig. 2b). This export may contribute to the increased FasL sensitivity of suspended compared with attached MCF10a cells (R.A.S. and S.M.F., unpublished work), which remains to be established. The export was not caused by anoikis-induced breakdown of the nuclear envelope, as evidenced by the aforementioned YFP-alone control, the fact that export preceded detectable caspase activation by several hours, and the insensitivity of export to the pan-caspase inhibitor zVAD-fmk (data not shown.) Moreover, the detachment of from matrix promoted the recruitment of endogenous FADD to cell-surface Fas-Fas antibody complexes (Fig. 2b), validating cell detachment as a stimulus for FADD export.

We used this assay to compare the export capabilities of various mutants of FADD. Interestingly, the S194A and DED mutations (that inhibited import) also inhibited export of FADD. Although the DED contained a leucine-rich sequence that was a potential signal for crm1-mediated export LTELKFLCL, mutations of the leucines in this sequence did not affect export; also, the crm1 inhibitor leptomycin B did not affect export of YFP-FADD-NLS at doses that completely prevented export of the crm1-cargo, protein kinase A-inhibitor (data not shown), suggesting that crm1 did not export FADD.

The observation that the same mutations prevented both FADD import and export and that a phosphorylation site was required for both suggested the involvement of a nucleocytoplasmic shuttle protein that interacted preferentially with phosphorylated cargoes. Such a protein has been identified recently in human cells: hmsn5/exportin-5 (53). Although this protein was originally dubbed an exportin, it was subsequently shown to act as an importin as well (54). FADD interacted efficiently with exportin-5/hmsn5 but not with crm1 in cotransfection experiments in 293T cells (Fig. 7, which is published as supporting information on the PNAS web site). Interestingly, the mutants of FADD that did not transport to or from the nucleus efficiently, S194A and Δ 1–80, also did not interact efficiently with exportin-5/hmsn5. Furthermore, GST-FADD protein recovered from transfected 293T cells interacted *in vitro* with purified exportin-5/hmsn5 protein in the presence of activated Ran protein [in accordance with the role of activated Ran in nuclear transport by exportin-5 (53)]; however, the same FADD protein first subjected to dephosphorylation did not (Fig. 7). Taken together, exportin-5/hmsn5 is a candidate FADD-shuttling protein, which remains to be confirmed by protein ablation experiments (complicated by the fact that exportin-5 is required for viability). Nevertheless, the data clearly define a role for Ser-194 phosphorylation in determining the localization of FADD protein.

FADD Interacts with MBD4. We hypothesized that FADD may carry out a novel function in the nucleus. Thus, a cDNA library derived from MCF-7 mammary adenocarcinoma cells was screened for FADD-interacting proteins in a yeast two-hybrid system.

Surprisingly, about one-third of the positive clones were fragments of MBD4. MBD4's interaction with FADD was highly specific in yeast, as several unrelated bait proteins failed to interact with it (Fig. 8a, which is published as supporting information on the PNAS web site). Using MBD4 deletion mutants expressed in the yeast two-hybrid system, we mapped the interacting region of MBD4 to amino acids 400–455, which is immediately upstream of the glycosylase domain (Fig. 8b). The regions of FADD required for MBD4 interaction were mapped similarly, indicating that the DED (amino acids 1–80) was required for the interaction but the carboxyl-terminal tail region




Fig. 3. FADD interacts with MBD4 in mammalian cells. (*Upper*) MCF10a lysates were immunoprecipitated (IP) with sheep anti-MBD4 antibody (M), anti-FADD polyclonal Ab (F), or preimmune serum (pre). Immunoprecipitates were analyzed by Western blotting using FADD mAb and a heavy v chain-specific anti-mouse secondary antibody. (*Lower*) Lysates from ^{32}P -labeled MCF10a cells were immunoprecipitated as above and the products were detected by autoradiography. Note that one of the two major antibody-specific bands precipitated with anti-FADD antibody comigrated with MBD4 (compare lanes M and F). The ≈ 90 -kDa band precipitated with FADD antibody was suspected to be MLH1, which was confirmed below. All of the lanes shown were derived from the same gel; intervening lanes were deleted for clarity.

(needed for exportin-5 interaction as shown above) was not required (Fig. 8c). To test the sufficiency of the DED for MBD4 interaction, noting that the DED alone was not expressed well in yeast or 293T cells, the interaction was assayed *in vitro* by using recombinant proteins. Interestingly, the DED of FADD was reproducibly found to interact more efficiently with MBD4 than did full-length FADD (Fig. 8c). The involvement of the DED of FADD suggested that MBD4 and caspase-8 might compete against each other for binding to FADD, which was confirmed *in vitro* (data not shown).

To test the FADD-MBD4 interaction in mammalian cells, we first cotransfected epitope-tagged forms of the two proteins into 293T cells, pulling down one protein on glutathione beads and probing a Western blot for the other in both combinations (Fig. 9a, which is published as supporting information on the PNAS web site). FADD and MBD4 interacted efficiently and specifically by this criterion. We then assayed for the interaction of the endogenous proteins by coimmunoprecipitation (Fig. 3). A sheep polyclonal antibody was prepared against the C-terminal domain of bacterially expressed human MBD4 and its specificity was confirmed (Fig. 5d). This antibody was used to immunoprecipitate MBD4 from MCF10a lysates. These immunoprecipitates (in contrast to those with preimmune sheep IgG) contained a FADD signal that was readily detectable on Western blots with exposure times of <10 s. To perform the converse experiment (noting that the sheep anti-MBD4 did not work well for Western blot detection and that both FADD and MBD4 are phosphoproteins), cellular proteins were metabolically labeled with ^{32}P , and lysates were immunoprecipitated with our polyclonal FADD antiserum. The immunoprecipitates were analyzed by autoradiography of an SDS gel, revealing a specific band that precisely comigrated with MBD4 immunoprecipitated from parallel lysates, as well as a band of the molecular mass of MLH1 (≈ 87 kDa). Indeed, endogenous FADD immunoprecipitated from MCF10a cells revealed the presence of MLH1 protein by Western blot analysis (Fig. 9b), and 293T cotransfection confirmed that the DED was required for this association as well. These data indicate that endogenous FADD and MBD4 proteins interact in MCF10a cells.




Fig. 4. MBD4 regulates FasL-induced apoptosis. MBD4 knockout or WT mice were injected with the agonistic Fas antibody Jo-2, and at the times indicated, intestinal crypt cells or hepatocytes were analyzed for apoptosis as described (47).

MBD4 Affects Apoptosis. The interaction of MBD4 with the caspase-8-activating protein FADD suggested that MBD4 might be capable of regulating apoptosis. To test this, we used our previously described MBD4 knockout mouse model (29). We recently observed evidence for a proapoptotic role of MBD4 with respect to DNA-damaging agents (O.J.S. and A.R.C., unpublished data). In light of the primary role of FADD in death receptor-induced apoptosis, WT control or MBD4 knockout mice were injected with the Fas-agonistic antibody Jo-2, which induces apoptosis rapidly in intestinal and hepatic epithelial cells that can be scored readily by histological analysis. Interestingly, the MBD4 knockout mice were reproducibly more sensitive (≈ 5.5 -fold in the small intestine) to apoptosis in this context (Fig. 4). To examine the effect of MBD4 on FasL responses in MEFs, we rescued *MBD4*^{-/-} MEFs with an HA-mouse-MBD4 retrovirus, generating mixed populations that expressed MBD4 at 3-fold above the WT MEF level (but substantially lower than the levels in established cell lines such as MCF10a; data not shown). This approach circumvented the comparison of cells from different embryos, which was confounded by variability. Surprisingly, MBD4 sensitized these cells, in contrast to the intestinal cells *in vivo*, to FasL-induced apoptosis (Fig. 10a, which is published as supporting information on the PNAS web site). This finding suggested that the effect of MBD4 on FasL-induced apoptosis depended on the cell type or the precise MBD4 expression level (which may in turn affect protein complex composition or MBD4 posttranslational modifications). Interestingly, MBD4 reexpression sensitized these MBD4-knockout cells to anoikis-related caspase activation as well (Fig. 10b).

Discussion

Nuclear Localization of FADD. FADD couples death receptors with initiator caspases (35–37). Thus, FADD is assumed to be primarily cytoplasmic. However, the evidence to support this assumption is limited to overexpressed FADD, which aggregates into “death effector filaments” (55, 56). These structures have not been observed for endogenous FADD, and, unlike endogenous FADD (R.A.S. and S.M.F., unpublished data) are Triton-insoluble (56). Thus, the localization of endogenous FADD protein was unexplored to our knowledge until the present report. The localization of FADD reported here does not imply that 100% of FADD is nuclear: clearly, the well-documented death receptor adaptor function of FADD logically implies that this is not the case. Thus, either there is a constitutive but minor cytoplasmic pool of FADD for this purpose or costimulatory signals for Fas signaling such as lack of cell-matrix adhesion (R.A.S. and S.M.F., unpublished data; refs. 43 and 44) stimulate the nuclear export of FADD. The latter is consistent with our results (Fig. 2b); thus, it will be interesting to determine how extracellular signals regulate FADD localization, as this could potentially modulate death ligand sensitivity. Control of Ser-194

phosphorylation, which is required for import/export and exportin-5 interaction, is likely to play a key role.

Significance of the FADD-MBD4 Interaction. MBD4 and FADD interacted with each other, suggesting a novel linkage between genome surveillance/DNA repair and apoptosis. Consistent with this finding, MBD4 was shown herein to control apoptosis. Preliminary data (not shown) using short-interfering RNA to reduce MBD4 protein levels in epithelial cell lines support this conclusion. The fact that MBD4 regulates FasL responses clearly implicates a functional connection between MBD4 and FADD, although more mechanistic information will be needed to conclude that MBD4 controls apoptosis by its direct FADD interaction.

Metazoan cells couple genome surveillance to apoptosis (reviewed in refs. 1, 12, and 57) to eliminate genetically aberrant and potentially neoplastic cells. We propose that MBD4-mediated genome surveillance is coupled directly to nuclear FADD, an adaptor protein implicated in multiple apoptotic responses (36–42). MBD4 is thought to specifically repair GT mismatches resulting from the spontaneous deamination of methylcytosine (25), the most frequent cause of point mutations in the human genome (28). In fact, MBD4 knockout mice show a mutator phenotype that leads to enhanced spontaneous carcinoma frequency in the *min* background (29). Thus, one compelling function for the MBD4–FADD complex would be to couple extensive “GT mismatch signals” to apoptosis.

The ability of MBD4 to regulate apoptotic responses to diverse DNA lesions (O.J.S. and A.R.C., unpublished data) or stimuli not apparently causing DNA damage is more challenging to explain. First, MBD4 interacts with MLH1 protein, and the latter promotes apoptosis triggered by a wide variety of DNA damage types (7–11), possibly because of its involvement in a large multifunctional DNA repair complex (58). Second, although FasL and anoikis are not considered DNA-damaging, they rapidly activate caspases, in turn activating nucleases that cause double-strand DNA breaks (59, 60). The latter would elicit DNA damage signals, thus activating caspases further in a feed-forward loop that finalizes the cell’s commitment to apoptosis. The possible involvement of FADD and MBD4 in this amplification process, which would explain the proapoptotic effects of MBD4, remains to be determined.

In the context of intestinal crypt cells *in vivo*, MBD4 paradoxically suppressed FasL-induced apoptosis. Cell context-dependent effects of a gene knockout on apoptosis are not unprecedented (cf. ref. 61); this likely reflects cell-type differences in apoptotic signaling mechanisms. Conceivably, MBD4 sequesters FADD in the nucleus, thus inhibiting Fas function in this context. Alternatively, the relative concentrations of FADD, MBD4, and caspase-8 may be critical for the apoptotic output, because MBD4 at low concentrations promoted FADD–caspase-8 interaction but at high concentrations inhibited *in vitro* (data not shown).

MBD4 is frequently mutated in human colorectal carcinoma cells, most commonly by frameshifts in the A10 repeat at position 301–310 (31–33), which would frameshift the downstream sequences including the glycosylase domain, MLH1 interaction domain, and FADD interaction domain. It will be of interest to mutationally inactivate each of these three functions independently to determine their contributions to apoptosis and understand whether this frameshift is potentially advantageous for tumor growth.

Finally, it has been reported that FADD is required for optimal cell cycle progression of activated T lymphocytes (62) and epithelial cells (R.A.S. and S.M.F., unpublished observations). When combined with the current observation that FADD is a component of a genome surveillance complex, one implication is that this complex may function in a cell cycle checkpoint with MLH1 or MBD4 to recognize the damage and FADD to arrest or promote progression through S phase.

We thank Ed Monosov and Souad Rahmouni for help with microscopy, Jean-Francois Cote and Miya Fujimoto for help with production of baculovirus proteins, Erica Golemis for advice and reagents for the yeast two-hybrid screens, Astar Winoto for the FADD-knockout MEFs, Ian Macara for a sample of exportin-5 protein, Carolyn Ho and Danielle Loughran for technical assistance, and Steve Linke and Robert Abraham for useful critique of the manuscript. The project was supported by National Institutes of Health Grant PO1 CA69381 (to S.M.F.), a Department of Defense Breast Cancer award (DAMD 17-00-0170) (to S.M.F.), a Canadian Institute of Health Research–Institut de Recherche Scientifique sur le Cancer Fellowship (to R.A.S.), and grants from Cancer Research U.K. (to A.R.C. and A.B.).

- Abraham, R. T. (2001) *Genes Dev.* **15**, 2177–2196.
- Wang, J. Y. (2000) *Oncogene* **19**, 5643–5650.
- Khanna, K. K., Keating, K. E., Kozlov, S., Scott, S., Gatei, M., Hobson, K., Taya, Y., Gabrielli, B., Chan, D., Lees-Miller, S. P. & Lavin, M. F. (1998) *Nat. Genet.* **20**, 398–400.
- Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M. & Wang, J. Y. (1999) *Nature* **399**, 806–809.
- Kolodner, R. D. & Marsischky, G. T. (1999) *Curr. Opin. Genet. Dev.* **9**, 89–96.
- Bellacosa, A. (2001) *J. Cell Physiol.* **187**, 137–144.
- Hardman, R. A., Afshari, C. A. & Barrett, J. C. (2001) *Cancer Res.* **61**, 1392–1397.
- Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J. & Boothman, D. A. (2001) *Cancer Res.* **61**, 5193–5201.
- Zhang, H., Richards, B., Wilson, T., Lloyd, M., Cranston, A., Thorburn, A., Fishel, R. & Meuth, M. (1999) *Cancer Res.* **59**, 3021–3027.
- Humbert, O., Fiumicino, S., Aquilina, G., Branch, P., Oda, S., Zijno, A., Karran, P. & Bignami, M. (1999) *Carcinogenesis* **20**, 205–214.
- Aebi, S., Fink, D., Gordon, R., Kim, H. K., Zheng, H., Fink, J. L. & Howell, S. B. (1997) *Clin. Cancer Res.* **3**, 1763–1767.
- Bernstein, C., Bernstein, H., Payne, C. M. & Garewal, H. (2002) *Mutat. Res.* **511**, 145–178.
- Formstecher, E., Ramos, J. W., Fauquet, M., Calderwood, D. A., Hsieh, J. C., Canton, B., Nguyen, X. T., Barnier, J. V., Camonis, J., Ginsberg, M. H. & Chneiweiss, H. (2001) *Dev. Cell* **1**, 239–250.
- Roth, W., Stenner-Liewen, F., Pawlowski, K., Godzik, A. & Reed, J. C. (2002) *J. Biol. Chem.* **277**, 7501–7508.
- Zhan, Y., Hegde, R., Srinivasula, S. M., Fernandes-Alnemri, T. & Alnemri, E. S. (2002) *Cell Death Differ.* **9**, 439–447.
- Stegh, A. H., Schickling, O., Ehret, A., Scaffidi, C., Peterhansel, C., Hofmann, T. G., Grummt, I., Krammer, P. H. & Peter, M. E. (1998) *EMBO J.* **17**, 5974–5986.
- Zheng, L., Schickling, O., Peter, M. E. & Lenardo, M. J. (2001) *J. Biol. Chem.* **276**, 31945–31952.
- Doostzadeh-Cizeron, J., Yin, S. & Goodrich, D. W. (2000) *J. Biol. Chem.* **275**, 25336–25341.
- Paroni, G., Henderson, C., Schneider, C. & Brancolini, C. (2002) *J. Biol. Chem.* **277**, 15147–15161.
- Schickling, O., Stegh, A. H., Byrd, J. & Peter, M. E. (2001) *Cell Death Differ.* **8**, 1157–1168.
- Torii, S., Egan, D. A., Evans, R. A. & Reed, J. C. (1999) *EMBO J.* **18**, 6037–6049.
- Morgan, M., Thorburn, J., Pandolfi, P. P. & Thorburn, A. (2002) *J. Cell Biol.* **157**, 975–984.
- Hendrich, B. & Bird, A. (1998) *Mol. Cell Biol.* **18**, 6538–6547.
- Bellacosa, A., Cicchillitti, L., Schepis, F., Riccio, A., Yeung, A. T., Matsumoto, Y., Golemis, E. A., Genuardi, M. & Neri, G. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 3969–3974.
- Hendrich, B., Hardeland, U., Ng, H. H., Jiricny, J. & Bird, A. (1999) *Nature* **401**, 301–304.
- Petronzelli, F., Riccio, A., Markham, G. D., Seeholzer, S. H., Genuardi, M., Karbowski, M., Yeung, A. T., Matsumoto, Y. & Bellacosa, A. (2000) *J. Cell Physiol.* **185**, 473–480.
- Petronzelli, F., Riccio, A., Markham, G. D., Seeholzer, S. H., Stoerker, J., Genuardi, M., Yeung, A. T., Matsumoto, Y. & Bellacosa, A. (2000) *J. Biol. Chem.* **275**, 32422–32429.
- Krawczak, M., Ball, E. V. & Cooper, D. N. (1998) *Am. J. Hum. Genet.* **63**, 474–488.

29. Millar, C. B., Guy, J., Sansom, O. J., Selfridge, J., MacDougall, E., Hendrich, B., Keightley, P. D., Bishop, S. M., Clarke, A. R. & Bird, A. (2002) *Science* **297**, 403–405.
30. Boland, C. R. (2000) *Ann. N.Y. Acad. Sci.* **910**, 50–59; discussion 59–61.
31. Bader, S., Walker, M., Hendrich, B., Bird, A., Bird, C., Hooper, M. & Wylie, A. (1999) *Oncogene* **18**, 8044–8047.
32. Bader, S., Walker, M. & Harrison, D. (2000) *Br. J. Cancer* **83**, 1646–1649.
33. Riccio, A., Aaltonen, L. A., Godwin, A. K., Loukola, A., Percesepe, A., Salovaara, R., Masciullo, V., Genuardi, M., Paravatou-Petsotas, M., Bassi, D. E., *et al.* (1999) *Nat. Genet.* **23**, 266–268.
34. Bellacosa, A. (2001) *Cell Death Differ.* **8**, 1076–1092.
35. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H. & Peter, M. E. (1995) *EMBO J.* **14**, 5579–5588.
36. Chinnaiyan, A. M., O'Rourke, K., Tewari, M. & Dixit, V. M. (1995) *Cell* **81**, 505–512.
37. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H. & Wallach, D. (1995) *J. Biol. Chem.* **270**, 7795–7798.
38. Micheau, O., Solary, E., Hammann, A. & Dimanche-Boitrel, M. T. (1999) *J. Biol. Chem.* **274**, 7987–7992.
39. Frisch, S. M. (1999) *Curr. Biol.* **9**, 1047–1049.
40. Rytomaa, M., Martins, L. M. & Downward, J. (1999) *Curr. Biol.* **9**, 1043–1046.
41. Shao, R. G., Cao, C. X., Nieves-Neira, W., Dimanche-Boitrel, M. T., Solary, E. & Pommier, Y. (2001) *Oncogene* **20**, 1852–1859.
42. Yuan, X. J. & Whang, Y. E. (2002) *Oncogene* **21**, 319–327.
43. Shain, K. H., Landowski, T. H. & Dalton, W. S. (2002) *J. Immunol.* **168**, 2544–2553.
44. Aoudjit, F. & Vuori, K. (2001) *J. Cell Biol.* **152**, 633–643.
45. Bhattacharya, D., Logue, E., Bakkour, S., DeGregori, J. & Sha, W. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 8838–8843.
46. Toft, N. J., Winton, D. J., Kelly, J., Howard, L. A., Dekker, M., te Riele, H., Arends, M. J., Wylie, A. H., Margison, G. P. & Clarke, A. R. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 3911–3915.
47. Kuang, A. A., Diehl, G. E., Zhang, J. & Winoto, A. (2000) *J. Biol. Chem.* **275**, 25065–25068.
48. Gurney, T., Jr., & Foster, D. N. (1977) *Methods Cell Biol.* **16**, 45–68.
49. Gurney, T., Jr., & Collard, M. W. (1984) *Anal. Biochem.* **139**, 25–34.
50. Scaffidi, C., Volkland, J., Blomberg, I., Hoffmann, I., Krammer, P. H. & Peter, M. E. (2000) *J. Immunol.* **164**, 1236–1242.
51. Rochat-Steiner, V., Becker, K., Micheau, O., Schneider, P., Burns, K. & Tschopp, J. (2000) *J. Exp. Med.* **192**, 1165–1174.
52. Eberstadt, M., Huang, B., Chen, Z., Meadows, R. P., Ng, S. C., Zheng, L., Lenardo, M. J. & Fesik, S. W. (1998) *Nature* **392**, 941–945.
53. Brownawell, A. M. & Macara, I. G. (2002) *J. Cell Biol.* **156**, 53–64.
54. Yoshida, K. & Blobel, G. (2001) *J. Cell Biol.* **152**, 729–740.
55. Perez, D. & White, E. (1998) *J. Cell Biol.* **141**, 1255–1266.
56. Siegel, R. M., Martin, D. A., Zheng, L., Ng, S. Y., Bertin, J., Cohen, J. & Lenardo, M. J. (1998) *J. Cell Biol.* **141**, 1243–1253.
57. Wahl, G. M. & Carr, A. M. (2001) *Nat. Cell Biol.* **3**, E277–E286.
58. Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J. & Qin, J. (2000) *Genes Dev.* **14**, 927–939.
59. Nagata, S. (2000) *Exp. Cell Res.* **256**, 12–18.
60. Kovacsovics, M., Martinon, F., Micheau, O., Bodmer, J. L., Hofmann, K. & Tschopp, J. (2002) *Curr. Biol.* **12**, 838–843.
61. Xu, Y. & Baltimore, D. (1996) *Genes Dev.* **10**, 2401–2410.
62. Zhang, J., Kabra, N. H., Cado, D., Kang, C. & Winoto, A. (2001) *J. Biol. Chem.* **276**, 29815–29818.